Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Silver, Daniel J  [Clear All Filters]
2023
Mitchell K, Sprowls SA, Arora S, Shakya S, Silver DJ, Goins CM, Wallace L, Roversi G, Schafer R, Kay K, et al. WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. Genes Dev. 2023.
2021
Silver DJ, Roversi GA, Bithi N, Wang SZ, Troike KM, Neumann CKa, Ahuja GK, Reizes O, J Brown M, Hine C, et al. Severe consequences of a high-lipid diet include hydrogen sulfide dysfunction and enhanced aggression in glioblastoma. J Clin Invest. 2021.
2020
Turaga SM, Silver DJ, Bayik D, Paouri E, Peng S, Lauko A, Alban TJ, Borjini N, Stanko S, Naik U, et al. JAM-A functions as a female microglial tumor suppressor in glioblastoma. Neuro Oncol. 2020.
2019
Mulkearns-Hubert EE, Torre-Healy LA, Silver DJ, Eurich JT, Bayik D, Serbinowski E, Hitomi M, Zhou J, Przychodzen B, Zhang R, et al. Development of a Cx46 Targeting Strategy for Cancer Stem Cells. Cell Rep. 2019;27(4):1062-1072.e5.
2016
Otvos B, Silver DJ, Mulkearns-Hubert EE, Alvarado AG, Turaga SM, Sorensen MD, Rayman P, Flavahan WA, Hale JS, Stoltz K, et al. Cancer stem cell-secreted macrophage migration inhibitory factor stimulates myeloid derived suppressor cell function and facilitates glioblastoma immune evasion. Stem Cells. 2016.
Dermawan JKam Tai, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, et al. Pharmacological targeting of the histone chaperone complex FACT preferentially eliminates glioblastoma stem cells and prolongs survival in preclinical models. Cancer Res. 2016.